Yazar "Agüloğlu, Nurşin" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    The prognostic relationship of 18F-FDG PET/CT metabolic and volumetric parameters in metastatic ALK plus NSCLC
    (Lippincott Williams & Wilkins, 2022) Agüloğlu, Nurşin; Aksu, Ayşegül; Unat, Damla S.; Akyol, Murat
    ObjectiveThe aim of this study is to determine the role of metabolic and volumetric parameters obtained from 18Fluorine-Fluorodeoxyglucose PET/computed tomography (18F-FDG PET/CT) imaging on progression-free survival (PFS) and overall survival (OS) in patients with advanced nonsquamous cell lung carcinoma (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement.MethodsPre and post-treatment PET/CT images of the ALK + NSCLC patients between January 2015 and July 2020 were evaluated. The highest standardized uptake value (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) values were obtained from pre-tyrosine kinase inhibitor (TKI) basal PET/CT (PETpre) and post-TKI PET/CT (PETpost) images. Total MTV (tMTV) and total TLG (tTLG) values were calculated by summing MTV and TLG values in all tumor foci. The change (Delta) in pSUVmax, pMTV, pTLG, tMTV and tTLG before and after treatment was calculated.The relationship of these parameters with OS and PFS was analyzed.ResultstTLG(pre), tMTV(pre), pTLG(pre), pMTV(pre), increment SUVmax, increment tMTV and increment tTLG values were found to be associated with OS; increment tMTV, increment tTLG, tTLG(pre), tMTV(pre), pTLG(pre) and pMTV(pre) were associated with PFS. The cutoff values in both predicting OS and PFS were calculated as -31.6 and 391.1 for increment tMTV and tTLG(pre), respectively. In Cox regression analysis, increment tMTV and stage for OS and increment tMTV and tTLGpre for PFS were obtained as prognostic factors.ConclusionsMetabolic and volumetric parameters, especially TLG values in the whole body before treatment and change in whole body MTV value, obtained from PET/CT may be useful in predicting prognosis and determining treatment strategies for patients with advanced ALK + NSCLC.
  • Küçük Resim
    Öğe
    The prognostic value of F-18-FDG PET/CT metabolic parameters in predicting treatment response before EGFR TKI treatment in patients with advanced lung adenocarcinoma
    (Galenos Publ House, 2022) Agüloğlu, Nurşin; Akyol, Murat; Komek, Halil; Katgı, Nuran
    Objectives: This study makes a retrospective examination of exploring the prognostic value of (18)fluorine-fluorodeoxyglucose (F-18-FDG) positron emission tomography/computed tomography (PET/CT) related metabolic-volumetric variables, nutritional status, and immune and inflammatory markers on progression-free survival (PFS) and overall survival (OS) in advanced adenocarcinoma patients with positive epidermal growth factor receptor (EGFR) mutations undergoing EGFR tyrosine kinase inhibitor (TKI) therapy. Methods: A retrospective examination was made of patients diagnosed with lung adenocarcinoma who underwent F-18-FDG PET/CT imaging for staging maximum four weeks before starting treatment, between January 2015 and July 2020. Included in the study were 68 patients identified histopathologically to have locally advanced/metastatic EGFR mutation-positive adenocarcinoma, and who underwent EGFR TKI therapy. The laboratory data of the patients, obtained 15 days before imaging performed for PET/CT staging, were evaluated. Results: Metabolic tumor volume, modified Glasgow prognostic score and locally advanced disease were identified as independent prognostic parameters for PFS (p= 0.004, p=0.029, p=0.016, respectively). A univariate Cox regression analysis revealed albumin/alkaline phosphatase and tumor size to be significant parameters for prognosis (p=0.033, p=0.043, respectively). A multivariate Cox regression analysis revealed that none of the parameters were predictive or OS. Conclusion: The parameters of F-18-FIDG PET/CT, especially the volumetric parameters, were found to be strong prognostic factors with statistical significance for predicting PFS. We believe that these parameters are important prognostic markers that should be evaluated together in the management and follow-up of patients with EGFR mutation-positive adenocarcinoma.